Disc Medicine, Inc. $IRON Shares Sold by UBS Group AG

UBS Group AG decreased its position in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 32.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 116,112 shares of the company’s stock after selling 55,511 shares during the quarter. UBS Group AG’s holdings in Disc Medicine were worth $9,220,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of IRON. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Disc Medicine by 22.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock valued at $756,000 after acquiring an additional 2,807 shares during the period. Millennium Management LLC boosted its holdings in shares of Disc Medicine by 1,277.1% during the first quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock valued at $5,386,000 after acquiring an additional 100,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Disc Medicine by 3.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock valued at $4,793,000 after acquiring an additional 3,454 shares during the period. Legal & General Group Plc boosted its holdings in shares of Disc Medicine by 18.0% during the second quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock valued at $1,276,000 after acquiring an additional 3,682 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Disc Medicine by 21.6% during the second quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock valued at $891,000 after acquiring an additional 2,983 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IRON shares. Stifel Nicolaus reduced their price target on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Wells Fargo & Company boosted their price target on shares of Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Truist Financial reduced their price target on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Finally, Wedbush reduced their price target on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $105.30.

Insider Activity at Disc Medicine

In other news, CFO Jean M. Franchi sold 6,257 shares of the company’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $69.24, for a total value of $433,234.68. Following the transaction, the chief financial officer owned 64,333 shares in the company, valued at $4,454,416.92. This represents a 8.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William Jacob Savage sold 5,731 shares of the company’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $66.38, for a total value of $380,423.78. Following the completion of the transaction, the insider owned 79,480 shares in the company, valued at $5,275,882.40. This represents a 6.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 59,410 shares of company stock valued at $3,840,013. Corporate insiders own 3.76% of the company’s stock.

Disc Medicine Price Performance

Shares of NASDAQ IRON opened at $66.86 on Friday. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of -10.10 and a beta of 0.93. The firm has a 50-day moving average of $65.42 and a two-hundred day moving average of $75.28.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, analysts expect that Disc Medicine, Inc. will post -6.78 earnings per share for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.